BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. J Dig Dis. 2013;14:446-450. [PMID: 23615131 DOI: 10.1111/1751-2980.12065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
2 Yamazhan T, Kurtaran B, Pullukçu H, Yüksel E, Özkaya D, Taşbakan MI, Sipahi OR, Durusoy R, Aksu HSZ. Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres. Journal of Chemotherapy 2013;26:339-41. [DOI: 10.1179/1973947813y.0000000152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther. 2011;33:501-513. [PMID: 21198707 DOI: 10.1111/j.1365-2036.2010.04555.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
4 Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006-1011. [PMID: 22245886 DOI: 10.1016/j.jhep.2011.12.007] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 12.3] [Reference Citation Analysis]
5 Rahman MA, Ueda K, Honda T. A Traditional Chinese Medicine, Maoto, Suppresses Hepatitis B Virus Production. Front Cell Infect Microbiol 2020;10:581345. [PMID: 33553000 DOI: 10.3389/fcimb.2020.581345] [Reference Citation Analysis]
6 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
7 Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532 [PMID: 24627588 DOI: 10.3748/wjg.v20.i10.2515] [Cited by in CrossRef: 190] [Cited by in F6Publishing: 176] [Article Influence: 23.8] [Reference Citation Analysis]
8 Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother. 2015;59:4121-4128. [PMID: 25941216 DOI: 10.1128/AAC.00249-15] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
9 Yap DYH, Chan TM. Evolution of hepatitis B management in kidney transplantation. World J Gastroenterol 2014; 20(2): 468-474 [PMID: 24574715 DOI: 10.3748/wjg.v20.i2.468] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
10 Köse Ş, Tatli Kiş T, Atalay S. Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy. J Chemother 2019;31:209-13. [PMID: 30963812 DOI: 10.1080/1120009X.2019.1597420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Stasi C, Rosselli M, Zignego AL, Laffi G, Milani S. Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions. Hepatol Res. 2014;44:9-16. [PMID: 23607322 DOI: 10.1111/hepr.12116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol. 2013;58:898-903. [PMID: 23376362 DOI: 10.1016/j.jhep.2013.01.029] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
13 Sonneveld MJ, Janssen HL. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int 2011;31 Suppl 1:78-84. [PMID: 21205142 DOI: 10.1111/j.1478-3231.2010.02384.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
14 Stasi C, Zignego AL, Laffi G, Rosselli M. The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis. J Viral Hepat. 2011;18:525-532. [PMID: 21762284 DOI: 10.1111/j.1365-2893.2010.01418.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
15 Tavis JE, Lomonosova E. NVR 3-778 Plus Pegylated Interferon-α Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3? Gastroenterology 2018;154:481-2. [DOI: 10.1053/j.gastro.2018.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ali L, Idrees M, Ali M, Rehman IU, Hussain A, Afzal S, Butt S, Saleem S, Munir S, Badar S. An overview of treatment response rates to various anti-viral drugs in Pakistani hepatitis B virus infected patients. Virol J 2011;8:20. [PMID: 21235813 DOI: 10.1186/1743-422X-8-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, Guitard J, Izopet J, Alric L, Kamar N. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation. 2011;91:916-920. [PMID: 21325995 DOI: 10.1097/tp.0b013e3182100f59] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
18 Mui UN, Haley CT, Vangipuram R, Tyring SK. Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus. J Am Acad Dermatol 2019;81:23-41. [PMID: 30502415 DOI: 10.1016/j.jaad.2018.10.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Boglione L, D'avolio A, Cariti G, Milia MG, Simiele M, De Nicolò A, Ghisetti V, Di Perri G. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013;20:e11-9. [DOI: 10.1111/jvh.12018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
20 Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013;58:872-80. [PMID: 23553752 DOI: 10.1002/hep.26436] [Cited by in Crossref: 154] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
21 Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 2015;35:1540-8. [DOI: 10.1111/liv.12725] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]